HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Amato, A. A. Articles by Kissel, J. T. Search for Related Content PubMed PubMed Citation Articles by Amato, A. A. Articles by Kissel, J. T.

Inclusion body myositis

Treatment with intravenous immunoglobulin

Department of Neurology (Drs. Amato and Pappert), Wilford Hall Medical Center, Lackland Air Force Base, TX; the Department of Neurology (Dr. Barohn), University of Texas Southwestern Medical Center, Dallas, TX; the Division of Neurology, Department of Medicine (Dr. Jackson), The University of Texas Health Science Center at San Antonio, San Antonio, TX; and the Department of Neurology (Drs. Sahenk and Kissel), The Ohio State University School of Medicine, Columbus, OH.

We report the results of nine patients with inclusion body myositis treated with intravenous immunoglobulin in an open-label uncontrolled study. None of our patients improved on objective manual muscle testing or functional disability scores. One patient developed mild neutropenia, complicating the intravenous immunoglobulin treatment. Our results do not exclude the possibility that intravenous immunoglobulin could be beneficial in some patients by slowing the rate of deterioration or perhaps stabilizing the disease. However, given the lack of objective improvement and high cost of treatment, we would not recommend intravenous immunoglobulin in the treatment of inclusion body myositis unless a blinded, controlled trial demonstrates clear benefit.

Address correspondence and reprint requests to Dr. Anthony A. Amato, WHMC/PSMN, 2200 Bergquist Dr, Ste 1, Lackland AFB, TX 78236-5300.

Received November 8, 1993. Accepted in final form February 7, 1994.

This article has been cited by other articles:

				A A Amato and R J Barohn Inclusion body myositis: old and new concepts J. Neurol. Neurosurg. Psychiatry, November 1, 2009; 80(11): 1186 - 1193. [Abstract] [Full Text] [PDF]

				C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al. Intravenous immunoglobulin in neurological disease: a specialist review J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 440 - 448. [Abstract] [Full Text] [PDF]

				Randomized pilot trial of {beta}INF1a (Avonex) in patients with inclusion body myositis Neurology, November 13, 2001; 57(9): 1566 - 1570. [Abstract] [Full Text] [PDF]

				M. C. Dalakas, B. Koffman, M. Fujii, S. Spector, K. Sivakumar, and E. Cupler A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM Neurology, February 13, 2001; 56(3): 323 - 327. [Abstract] [Full Text] [PDF]

				P. S. Sorensen Intravenous Immunoglobulin Treatment in Neurologic Disorders: Yes Arch Neurol, August 1, 1999; 56(8): 1025 - 1027. [Full Text] [PDF]

				F L Mastaglia, B A Phillips, and P J Zilko Immunoglobulin therapy in inflammatory myopathies J. Neurol. Neurosurg. Psychiatry, July 1, 1998; 65(1): 107 - 110. [Abstract] [Full Text]